Drug Profile
Research programme: type-2 diabetes mellitus therapeutics - ProMining Therapeutics/Roche
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ProMining Therapeutics; Roche
- Class Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in Israel (PO)
- 17 Dec 2012 Early research in Type-2 diabetes mellitus in Israel (PO)